|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, August 26, 2016 ) Publisher projects the Psoriasis market in 8MM to experience modest growth during the forecast period at a CAGR of 7.26%. This growth will be driven primarily by the highly anticipated arrivals of promising systemic therapies- interleukin-17 (IL-17) inhibitors (Cosentyx, guselkumab and tildrakizumab), interleukin-23 (IL-23) inhibitors (ixekizumab and brodalumab) as well as phsophodiesterase (PDE4) inhibitor- Otezla (apremilast). Nevertheless, looming patent expiries of high-grossing branded drugs- especially TNF inhibitors, Humira, Enbrel and Remicade, in the US, 5EU (France, Germany, Italy, Spain, UK), and Japan, along with rapid global developmentsof biosimilars are expected to spread the growth throughout the different classes of products, away from the branded TNF inhibitors which have traditionally been the main driver of growth in the prior years.
The US is the largest psoriasis market, although it does not have the highest diagnosed prevalence rates of psoriasis. The US will experience major brand erosion beginning with Humira in 2016, followed by Remicade in 2018 and Stelara in 2023; Enbrel is protected until 2028. Biosimilars are likely to launch in 2016 for adalimumab and will take some patient share away from Humira. Although biosimilar uptake will be favored for its cost effectiveness, unclear requirements for demonstrating interchangeability with originator biologics, as well as strong preferences for originator products among dermatologists, could be hindering factors.
Free sample brochure @ http://www.reportsweb.com/psoriasis-us-drug-forecast-and-market-analysis-to-2024
Scope
- Overview of Psoriasis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2014-2024.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Psoriasis market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Psoriasis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2014-2024 in US.
Discount Copy is available @ http://www.reportsweb.com/inquiry&RW0001317251/discount
About Us
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers.
Contact Us:
Phone: +1-646-491-9876
Email: sales@reportsweb.com
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
